This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vostrov, S. N.
Right arrow Articles by Firsov, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vostrov, S. N.
Right arrow Articles by Firsov, A. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2000, p. 879-884, Vol. 44, No. 4
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Comparative Pharmacodynamics of Gatifloxacin and Ciprofloxacin in an In Vitro Dynamic Model: Prediction of Equiefficient Doses and the Breakpoints of the Area under the Curve/MIC Ratio

Sergey N. Vostrov, Olga V. Kononenko, Irene Y. Lubenko, Stephen H. Zinner,dagger and Alexander A. Firsov*

Division of Infectious Diseases, Roger Williams Medical Center, Rhode Island Hospital, Brown University, Providence, Rhode Island

Received 8 April 1999/Returned for modification 18 September 1999/Accepted 10 January 2000

To demonstrate the impact of the pharmacokinetics of gatifloxacin (GA) relative to those of ciprofloxacin (CI) on the antimicrobial effect (AME), the killing and regrowth kinetics of two differentially susceptible clinical isolates each of Staphylococcus aureus, Escherichia coli, and Klebsiella pneumoniae were studied. With each organism, a series of monoexponential pharmacokinetic profiles of GA (half-life [t1/2], 7 h) and CI (t1/2 = 4 h) were simulated to mimic different single doses of GA and two 12-h doses of CI. The respective eightfold ranges of the ratios of the area under the concentration-time curve (AUC) to the MIC were 58 to 466 and 116 to 932 (µg · h/ml)/(µg/ml). The species- and strain-independent linear relationships observed between the intensity of AME (IE) and log AUC/MIC were not superimposed for GA and CI (r2 = 0.99 in both cases). The predicted AUC/MIC ratio for GA that might be equivalent to a clinically relevant AUC/MIC breakpoint for CI was estimated to be 102 rather than 125 (µg · h/ml)/(µg/ml). The respective MIC breakpoints were 0.32 µg/ml (for a 400-mg dose of GA) and 0.18 µg/ml (for two 500-mg doses of CI). On the basis of the IE-log AUC/MIC relationships, equiefficient 24-h doses (D24hs) of GA and CI were calculated for hypothetical strains of S. aureus, E. coli, and K. pneumoniae for which the MICs were equal to the MICs at which 50% of isolates are inhibited. To provide an "acceptable" IE equal to 200 (log CFU/ml) · h, i.e., the IE provided by AUC/MIC of 125 (µg · h/ml)/(µg/ml) for ciprofloxacin, the D24hs of GA for all three organisms were much lower (115, 30, and 60 mg) than the clinically proposed 400-mg dose. Although the usual dose of CI (two doses of 500 mg) would be in excess for E. coli and K. pneumoniae (D24h = two doses of 40 mg and two doses of 115 mg, respectively), even the highest clinical dose of CI (two doses of 750 mg) might be insufficient for S. aureus (D24h, > two doses of 1,000 mg). The method of generalization of data obtained with specific organisms to other representatives of the same species described in the present report might be useful for prediction of the AMEs of new quinolones.


* Corresponding author. Present address: Department of Pharmacokinetics, Centre for Science & Technology LekBioTech, 8 Nauchny proezd, Moscow, 117246 Russia. Phone: 7 (095) 332-3435. Fax: 7 (095) 332-6307. E-mail: firsov{at}dol.ru.

dagger Present address: Mount Auburn Hospital, Cambridge MA, 02138.


Antimicrobial Agents and Chemotherapy, April 2000, p. 879-884, Vol. 44, No. 4
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Noreddin, A. M., Haynes, V. L., Zhanel, G. G. (2005). Pharmacokinetics and Pharmacodynamics of the New Quinolones. Journal of Pharmacy Practice 18: 432-443 [Abstract]  
  • Firsov, A. A., Lubenko, I. Y., Vostrov, S. N., Portnoy, Y. A., Zinner, S. H. (2005). Antistaphylococcal Effect Related to the Area under the Curve/MIC Ratio in an In Vitro Dynamic Model: Predicted Breakpoints versus Clinically Achievable Values for Seven Fluoroquinolones. Antimicrob. Agents Chemother. 49: 2642-2647 [Abstract] [Full Text]  
  • Schentag, J. J, Meagher, A. K, Forrest, A. (2003). Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates: Part 1: In Vitro and Animal Models. The Annals of Pharmacotherapy 37: 1287-1298 [Abstract] [Full Text]  
  • Firsov, A. A., Vostrov, S. N., Lubenko, I. Y., Drlica, K., Portnoy, Y. A., Zinner, S. H. (2003). In Vitro Pharmacodynamic Evaluation of the Mutant Selection Window Hypothesis Using Four Fluoroquinolones against Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 1604-1613 [Abstract] [Full Text]  
  • Zinner, S. H., Firsov, A. A., Gilbert, D., Simmons, K., Lubenko, I. Yu. (2001). The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: prediction of equiefficient doses. J Antimicrob Chemother 48: 821-826 [Abstract] [Full Text]